Krystal Biotech (KRYS) Enterprise Value (2017 - 2026)

Krystal Biotech has reported Enterprise Value for 11 years, with the latest figure at -$845.6 million in Q2 2026.

• Enterprise Value for Q2 2026 came in at -$845.6 million, down 24.0% year-over-year; the trailing twelve-month figure through Jun 2026 was -$845.6 million (down 24.0% YoY), and the FY2025 annual result was -$827.8 million, down 38.54% from the prior year.
• Enterprise Value retreated to -$845.6 million in Q2 2026, from -$823.4 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$350.4 million in Q1 2023 and troughed at -$845.6 million in Q2 2026.
• A 5-year average of -$575.9 million and a median of -$560.8 million in 2023 frame the typical range for Enterprise Value.
• The widest annual swing landed in 2023, when Enterprise Value increased 19.38%; it then plunged 53.62% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$379.2 million in 2022, then slumped by 40.35% to -$532.2 million in 2023, then retreated by 12.28% to -$597.5 million in 2024, then slumped by 38.54% to -$827.8 million in 2025, then slipped by 2.16% to -$845.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$845.6 million in Q2 2026, -$823.4 million in Q1 2026, and -$827.8 million in Q4 2025.